BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EBGLYSS (lebrikizumab-lbkz) by Eli Lilly and Company is interleukin-13 antagonists [moa]. Approved for interleukin-13 antagonist [epc]. First approved in 2024.
Drug data last refreshed 17m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EBGLYSS (lebrikizumab-lbkz) is a monoclonal antibody that antagonizes interleukin-13, a key cytokine driver of type 2 inflammation. It is approved for patients with IL-13–mediated inflammatory conditions, targeting the underlying pathophysiology of Th2-driven disease. The drug represents a precision-targeted approach to blocking a specific immune pathway implicated in multiple allergic and fibrotic disorders.
Growth
Early commercial lifecycle presents growth opportunity; team expansion likely as label indications expand and market penetration increases.
Mechanism of Action
Interleukin-13 Antagonists
Pharmacologic Class:
Interleukin-13 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EBGLYSS offers entry into a newly launched, growth-stage biologic with significant label expansion potential. Early career positioning in growth phase provides visibility to market building, clinical development, and competitive strategy as IL-13 antagonism becomes standard of care.
Brand ManagerMedical Science Liaison
Worked on EBGLYSS at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.